Nureca Limited has informed the Exchange regarding 'Investor Presentation'.
NURECA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Nureca Limited, a digital-first healthcare company, released its Q4 & FY26 investor presentation. The company achieved a significant operational turnaround in FY26, posting an operating profit of ₹8.5 Cr compared to a loss of ₹7.5 Cr in FY25, after three consecutive years of losses. Q4 FY26 revenue grew 12% YoY to ₹35.4 Cr, while FY26 revenue reached ₹146.96 Cr (34% YoY growth). However, Q4 FY26 reported a PAT loss of ₹6.1 Cr due to investment fair value changes under IND AS, though FY26 PAT was positive at ₹2.1 Cr. The company is debt-free with 90%+ revenue from online sales, operates 285+ distributors across 29 states, and has 102 design patents with USFDA & CE approved products.
The turnaround to operational profitability is a positive signal for shareholders, though the Q4 PAT loss due to investment losses may cause short-term stock volatility. The strong revenue growth and EPS improvement (147% YoY to 2.1) indicate improving fundamentals.